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Abstract
Background: Dipeptidyl peptidase 4 (DPP4) and angiotensin-converting enzyme (ACE) are important target enzymes in
glycemic control and renovascular protection. Here, we studied the effect of NWT-03, an egg protein hydrolysate with
DPP4- and ACE-inhibitory activity, on renovascular damage in Zucker diabetic fatty (ZDF) rats. Comparisons were made to
rats treated with vildagliptin (VIL), included as a positive control for the effect of DPP4 inhibition.
Methods: ZDF rats received NWT-03 (1 g/kg/day) or VIL (3 mg/kg/day) from 10 to 25 weeks of age. Metabolic and renal
functions were assessed; the kidney was removed for histological analysis of glomerulosclerosis and expression of pro-
inflammatory/fibrotic markers (RT-PCR and Western blotting); and the aorta was removed for studies of endothelium-
dependent relaxation (EDR).
Findings: Hyperinsulinemic ZDF rats typically developed signs of type-2 diabetes and renovascular damage, as evidenced
by albuminuria, glomerulosclerosis, and impaired EDR. Neither NWT-03 nor VIL improved metabolic parameters; for VIL, this
was despite a 5-fold increase in glucagon-like peptide (GLP)-1 levels. NWT-03 and VIL both reduced renal interleukin (Il)-1b/
Il-13 mRNA expression and glomerulosclerosis. However, only NWT-03 additionally decreased renal tumor necrosis factor
(TNF)-a mRNA and P22phox protein expression, reduced albuminuria, and restored aortic EDR. Indomethacin added to the
organ bath instantly improved aortic EDR, indicating a role for cyclooxygenase (COX)-derived contractile prostanoids in
opposing relaxation in ZDF rats. This indomethacin effect was reduced by NWT-03, but not by VIL, and coincided with
decreased renal COX-1/2 protein expression.
Conclusion and Interpretation: Long-term supplementation with the egg protein hydrolysate NWT-03 attenuated
renovascular damage in this preclinical rat model of type 2 diabetes. A comparison to the DPP4-inhibitor VIL suggests that
the effects of NWT-03 were related to both ACE- and DPP4-inhibitory properties. The development of protein hydrolysates
with a multiple-targeting strategy may be of benefit to functional food formulations.
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Introduction
Food-derived bioactive peptides represent a source of health-
enhancing components that may be incorporated in functional
foods. The intrinsic bioactivities of the peptides encrypted in major
food proteins are latent until released and activated by enzymatic
hydrolysis, for example during gastrointestinal digestion [1].
Quantitative in silico analyses may be used to calculate bioactivity
in protein digests and identify good potential sources of peptides of
interest [2,3]. In such a search, we identified the egg protein
lysozyme as a potential precursor protein of angiotensin-convert-
ing enzyme (ACE)-inhibitory peptides upon digestion with
alcalase. The activity of this hydrolysate, termed NWT-03, was
confirmed in subsequent in vitro ACE-inhibition assays
(IC50 = 0.07 mg/mL) (Buikema et al., unpublished data). ACE-
inhibitors have emerged as important agents, not only in the
management of hypertension but also for their potential to reduce
cardiovascular risk and nephropathy; moreover, they provide
renovascular protection through different mechanisms beyond
their primary therapeutic actions [4,5]. This appears to be of
particular importance in patients with diabetes in whom kidney
disease is one of the most serious complications.
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Interestingly, our in vitro assays additionally highlighted the
potential of NWT-03 to inhibit dipeptidyl peptidase 4 (DPP4)
activity (IC50 = 0.9 mg/mL) (Buikema et al., unpublished data).
The latter enzyme degrades active glucagon-like peptide 1 (GLP-
1), a pro-glucagon-derived hormone secreted by intestinal L-cells
and pancreatic a-cells, that has profound effects on gut clearing
and insulin secretion in the gastrointestinal tract [6]. Because of
this action, stable GLP-1 analogues (e.g., exenatide) and DPP4
inhibitors, such as vildagliptin (VIL), have been developed for the
treatment of type 2 diabetes mellitus (DM2) [7]. Previous studies
with insulin-resistant rats have suggested that chronic treatment
with synthetic DPP4-inhibitors may improve impaired glucose
metabolism and dyslipidemia [8].
Whereas research in the field of bioactive peptide analysis and
functional food development has mostly followed single-target
strategies, network models suggest that partial inhibition of a small
number of targets can be more efficient than the complete
inhibition of a single target [9]. Given this, we hypothesized that
the egg protein hydrolysate NWT-03, which displays both ACE-
and DPP-4 inhibitory activity, might beneficially affect parameters
of renovascular damage development in DM2. To study this, we
supplemented the drinking water of Zucker diabetic fatty (ZDF)
rats with NWT-03 for 15 weeks, and then assessed renal damage
and vascular endothelial dysfunction. A parallel group of ZDF rats
treated with the commercially available DPP4-inhibitor VIL,
included as a positive control for the effect of DPP4-inhibition, was
studied concurrently.
Materials and Methods
Animals and study design
The protocols for animal care and use were in accordance with
the NIH Guide for the Care and Use of Laboratory Animals and
were approved by the Committee for Animal Experiments
(Dierexperimentencommissie, DEC) of the University of Gronin-
gen (Permit Number: DEC4809A and 25370A). Studies were
conducted using male obese ZDF (fa/fa) and Zucker lean control
(+/?) rats obtained from Charles River (France). Animals were
housed group-wise in standard cages and maintained on a 12:12-
hour light:dark cycle with free access to food (Purina 5008) and
water. After acclimatization, 10-week-old ZDF rats were randomly
assigned to receive 1 g/kg per day NWT-03 (n= 9) or 3 mg/kg
per day VIL (n = 7), or remained untreated (ZDF; n= 7). In
preliminary in vivo studies, oral administration of NWT-03 and
VIL as a single dose at the indicated concentrations induced a
significant inhibition of plasma DPP4-activity, an effect that was
more pronounced after VIL (Figure S1). Furthermore, in
spontaneously hypertensive rats (SHRs), 1 g/kg NWT-03 was
comparably effective in inhibiting plasma ACE-activity and
reducing systolic blood pressure after acute oral gavage (Figure
S2).
Long-term supplementation with NWT-03 or VIL via drinking
water was maintained for 15 weeks, during which body weight and
water intake were monitored and the amount of NWT-03 and
VIL were adjusted accordingly. Samples for determining meta-
bolic parameters were collected at the start and the end of the
study period. For the collection of urine, rats were housed
individually in a metabolic cage for 24 hours, and samples were
analyzed for glucose, albumin, and malondialdehyde (MDA).
Blood samples, collected from the tail vein during mild anesthesia
(2.0–2.5% isoflurane in oxygen), were analyzed for blood glucose,
HbA1c, cholesterol, free fatty acids (FFAs), and serum insulin; in
addition, GLP-1 levels were determined at the end of the study
period. Animals were sacrificed at the age of 25 weeks under
anesthesia, as described above. Systolic blood pressure and heart
rate were measured using a catheter-tip micro-manometer (Millar
Instruments, Germany) advanced into the aorta. A final blood
sample was drawn and the kidneys were flushed with saline, after
which kidneys and aorta were removed together. Part of the
kidney was fixed with 4% formaldehyde and another part was
snap-frozen in liquid nitrogen and stored at280uC. The aorta was
studied for endothelium-dependent relaxation (EDR) responses in
organ bath studies.
Bioanalytical procedures
Blood glucose and cholesterol were determined using Accu-
Chek Aviva and AccuTrend (both Roche Diagnostics, Almere,
The Netherlands) monitors, respectively; Hb1Ac was determined
using a DCA Vantage Analyzer (Siemens Healthcare Diagnostics
Inc., Deerfield, IL). Serum GLP-1 (Glucagon-Like Peptide-1
[Active] ELISA Kit; Millipore Corporation, Billerica, MA), insulin
([Rat] enzymatic immunoassay; ALPCO Diagnostics, Salem, NH),
and FFAs (Free Fatty Acid Quantification Kit; Biovision, Research
Products, Mountain View, CA) were determined using the
indicated commercial kits. Urinary glucose was confirmed using
a Diabur 5000 dipstick (Roche Diagnostics); color intensity was
categorized from 0 to 7, covering a range of 0–5% (g/dL) glucose.
Urinary albumin and creatinine were determined using a DCA
Vantage Analyzer (Siemens Healthcare Diagnostics Inc.), and
urinary MDA levels were assessed using a Malondialdehyde Assay
kit (NWK-MDA01; Northwest Life Science Specialties, LLC,
Vancouver, WA).
Light microscopy
Coronal tissue slices through the mid portion of the kidney were
fixed in 4% formaldehyde and embedded in paraffin, after which
sections (4 mm) were stained with periodic acid-Schiff (PAS) [10].
Subsequently, glomeruli were semi-quantitatively scored for focal
glomerulosclerosis (FGS) by light microscopy on a scale of 1 to 4,
as described previously [11]. FGS was scored positive when
mesangial expansion, mesangial cellularity, adhesion formation,
and capillary obliteration was present in one segment. If 25% of
glomerulus was affected, a score of 1 was adjudged, 50% was
scored as 2, 75% as 3, and 100% as 4. The ultimate score is then
obtained by multiplying the degree of change by the percentage of
glomeruli with the same degree of injury and adding these scores.
A total of 50 glomeruli per kidney were scored moving from cortex
to medulla and the average value per kidney (i.e. per animal)
calculated.
Immunohistochemistry
Immunohistochemistry was performed on paraffin-embedded
sections, as described previously [12]. After the section was
deparaffinized and dehydrated, two-step immunoperoxidase
staining was performed according to standard methods. Peroxi-
dase activity was developed by incubation with 3-amino-9-
ethylcarbazole (AEC; Dakopatts, Glostrup, Denmark). Negative
controls were performed by replacing primary antibodies with
PBS. The antibodies used were mouse monoclonal anti-a-smooth
muscle actin (a-SMA; DAKO, Denmark) for myofibroblasts, and
rabbit polyclonal anti-KIM-1 (kidney injury molecule 1; gener-
ously provided by Dr. H. van Goor, University Medical Center
Groningen, The Netherlands) for proximal tubular damage/
interstitial damage. To evaluate pre-fibrosis after diabetic injury,
the expression of a-SMA was measured using computer-assisted
morphometry. Total staining was evaluated at a magnification of
4006 using 15–20 fields per section. Glomeruli and arteries were
excluded from measurements. a-SMA staining was divided by the
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area measured and expressed as a percentage, and an average
score calculated per section. The expression of KIM-1, a marker of
tubular damage, was also measured using computer-assisted
morphometry. Total staining was evaluated at a magnification of
2006using 25 fields per section and expressed as average intensity
of staining. Evaluation of the stainings and morphometric analysis
were performed in a blinded manner.
RNA isolation and real-time PCR
Frozen kidney samples containing both cortex and medulla
were homogenized, and RNA was isolated using a kit (Qiagen,
Venlo, The Netherlands). cDNA was synthesized from total RNA
(1 mg) by reverse transcription (RT) and was used to analyze the
expression of interleukin (Il)-1b, Il-13, E-selectin, vascular cell
adhesion molecule (VCAM)-1, CD68, and tumor necrosis factor
(TNF)-a using a real-time polymerase chain reaction (PCR)
protocol, as described previously [13]. Quantification was
performed using Absolute QPCR SYBR Green reagents (Molec-
ular Probes, Leiden, The Netherlands) and a CFX384 Real-Time
PCR Detection System (Bio-Rad Laboratories, Inc., Hercules,
CA). Thermal cycling was carried out at 95uC for 15 minutes,
followed by 40 cycles with 95uC for 15 seconds and 60uC for
1 minute. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
was used as a housekeeping gene. The PCR primers used are
presented in Table S1.
Western blotting
Kidney tissues were homogenized in RIPA lysis buffer
(composition: 1% NP40, 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulfate (SDS), 10 mM b-mercapto-ethanol, 10 mg/ml
PMSF, 5 ml/ml aprotinin, 100 mM sodium orthovanadat, 5 ml/ml
benzamidine, 5 ml/ml pepstatine A, 5 ml/ml leupeptine in 16
PBS) on ice using an Ultra Turrax homogenizer, after which the
supernatants were collected and protein concentrations were
determined. After separating samples (50 mg) on 4–20% Precise
Protein Gels (Pierce, Rockford, IL), proteins were electrotrans-
ferred onto nitrocellulose membranes (Bio-Rad), and nonspecific
binding was blocked by incubating for 30 minutes with with 5%
skimmed milk in PBS. Thereafter, membranes were incubated
with primary antibodies overnight at 4uC, and then with
secondary antibodies for 1 hour at room temperature. Immuno-
reactive proteins were visualized by enhanced chemiluminescence
(SuperSignal West Pico Chemiluminescent Substrate; Thermo
Scientific, Pierce, Rockford, IL). The primary antibodies used
were rabbit polyclonal anti-P22phox (Santa Cruz Biotechnology,
Santa Cruz, CA), rabbit polyclonal anti-COX-1 (cyclooxygenase-
1; Alexis, San Diego, CA), mouse monoclonal anti-COX-2 (BD
Pharmingen, San Diego, CA), rabbit polyclonal anti-TXA2R
(thromboxane A2 receptor; Santa Cruz Biotechnology), and
mouse monoclonal GAPDH (Sigma, St. Louis, MO).
Vascular studies with isolated aortic rings
For isotonic displacement studies, the aorta was cleaned of fat
and connective tissue, cut into rings, and mounted in an organ
bath setup filled with Krebs solution bubbled with 95%O2/
5%CO2 at 37uC, as described previously [14]. Briefly, rings were
pre-constricted with 1 mmol/L phenylephrine, and EDR responses
(percent of pre-constriction) to 0.01–100 mmol/L acetylcholine
(ACh) and maximal endothelium-independent relaxation to
10 mmol/L sodium nitroprusside were studied; all concentrations
are final concentrations in the bath. The EDR response to ACh
was additionally studied in the presence of 10 mmol/L indometh-
acin, added to inhibit COX-derived prostanoids, as described
previously [15].
Treatment with drugs and other compounds
NWT-03 was produced by Food & Biomade Research
(Wageningen University, The Netherlands). Briefly, a solution of
5% lysozyme protein (Belovo) was hydrolyzed for 6 hours with a
2% (w/w) solution of alcalase enzyme (Novozyme) at an optimal
pH (pH 8) and temperature (60uC), After hydrolysis, the enzyme
was inactivated, the hydrolysate was centrifuged to remove
insoluble protein, and the supernatant was freeze dried. VIL
(Galvus Novartis) was obtained from the Hospital Pharmacy at the
University Medical Center Groningen, The Netherlands. The
KIM-1 antibody was generously provided by Dr. H. van Goor
(University Medical Center Groningen, Netherlands). All other
reagents were of analytical grade and were purchased from
commercial suppliers.
Statistical analysis
Data are expressed as means 6 SEMs. Untreated ZDF rats
were compared to lean controls using Student’s unpaired t-test.
The three experimental ZDF groups were compared among each
other using one-way analysis of variance (ANOVA) in combina-
tion with Dunnett post hoc analysis for multiple comparisons, using
untreated ZDF rats as a control group. Differences with a p-value
,0.05 in two-tailed tests were considered significant (SPPS 18.0;
SPSS Inc., Chicago, IL).
Table 1. Characteristics of ZDF and lean control rats at 10 and
25 weeks of age.
10 weeks 25 weeks
Lean
(n =7) ZDF (n=7)
Lean
(n =7) ZDF (n=7)
Body weight (g) 24665 34265*** 39364 427620
Left kidney
weight (mg)
- - 1263629 2154647***
Right kidney
weight (mg)
- - 1335642 2199674***
Hemodynamic parameters
Aorta HR (bpm) - - 26169 226614
Aorta SBP
(mmHg)




7.7660.24 12.3362.4 9.660.42 23.961.72***
Hb1Ac (%) 3.5160.03 5.3760.25*** 3.5760.04 9.5460.16***
Insulin (ng/mL) 29.162.6 243.3634.6*** 28.363.3 28.564.0
Cholesterol
(mmol/L)




2.860.6 33.3612.1* 1.960.5 77.4615.7**
Glucose
(category 0–7)
0.060.0 3.060.9* 0.060.0 .7.0
MDA:Creatinine 3.2260.27 4.1460.86 1.7461.99 4.4461.03*
24-h Urine
volume (mL)
6.760.5 20.867.1 11.461.3 74.868.2***
Abbreviations: HR, heart rate; bpm, beats per minute; SBP, systolic blood
pressure; MDA, malondialdehyde.
Data are means 6 SEMs (*p,0.05, **p,0.01 and ***p,0.001 vs. lean of same
age; t-test).
doi:10.1371/journal.pone.0046781.t001
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Results
ZDF rats as an animal model of DM2 with renovascular
damage (Table 1)
Metabolic parameters. At 10 weeks of age (the start of the
study), ZDF rats already showed increased body weight, first signs
of hyperglycemia (elevated blood glucose and HbA1c levels) and
hyperlipidemia (FFA: 0.2460.05 and 0.6560.18 mmol/L for lean
and ZDF, respectively; p,0.05), and increased serum insulin. The
additional presence of glucose in the urine (category 3 coloring,
corresponding to 0.5% [g/dL]) indicated the onset of diabetes,
whereas increased albumin levels in 24-hour urine samples
suggested the presence of early renal damage. Metabolic
parameters in ZDF rats profoundly worsened over time, with
blood cholesterol, glucose, and HbA1c levels doubling after the 15-
week study period; the levels of these parameters remained low in
lean controls. In contrast, serum insulin declined to lean levels in
ZDF rats, indicating progressive insulinopenia. Taken together
with a marked increase in urinary volume production and high
urinary glucose levels, these observations confirmed the progres-
sive development of a DM2 state in ZDF rats. These changes were
accompanied by a significant increase in urinary albumin
excretion and higher urinary MDA levels.
Renal damage. ZDF kidney sections showed positive immu-
nostaining and increased expression of a-SMA and KIM-1
(Figure 1), indicating the presence of mesangial cell proliferation
and renal injury, respectively. RT-PCR analyses showed increased
renal mRNA expression of all the inflammatory markers studied
and the development of structural renal damage. Specifically,
compared to lean controls, E-selectin was increased by 2-fold,
VCAM-1 by 2.1-fold, CD-68 by 5.5-fold, Il-1b by 2.1-fold, Il-13
by 1.8-fold, and TNFa by 1.7-fold in ZDF rats (Figure 2).
Figure 1. Renal expression of (A) a-SMA and (B) KIM-1. Shown are representative pictures of lean control rats (top left) and untreated ZDF rats
(top right), and ZDF rats supplemented with NWT-03 (bottom left) or treated with VIL (bottom right). Bars in the graphs represent the average per
group, presented as means 6 SEMs (*p,0.05 and **p,0.01 vs lean; ##p,0.01 vs ZDF).
doi:10.1371/journal.pone.0046781.g001
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Histological analyses of PAS-stained kidney sections showed a 5-
fold increase in FGS (Figure 3); kidney weights were also increased
in ZDF rats. Western blot analyses additionally revealed a 3.3-fold
increase in the abundance of renal P22phox protein (Figure 4),
implicated as a mediator of oxidative stress [16]. Renal COX-1
and COX-2 proteins were also increased (5.3- and 3.4-fold,
Figure 2. Renal mRNA expression of (A) E-selectin, (B) VCAM-1, (C) CD68, (D) Il-1b, (E) Il-13, and (F) TNFa. Shown are results for lean
controls and untreated ZDF rats, and ZDF rats supplemented with NWT-03 or treated with VIL. Target mRNA levels are expressed relative to those of
GAPDH and are presented as means 6 SEMs (*p,0.05, **p,0.01, and ***p,0.001, vs. lean; #p,0.05 and ##p,0.01 vs. ZDF).
doi:10.1371/journal.pone.0046781.g002
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respectively) in ZDF rats, whereas TXA2R was decreased by 3.7-
fold (Figure 4).
Vascular dysfunction. EDR responses to ACh in aortas of
ZDF rats were significantly impaired compared to those of lean
rats (Figure 5A). Since maximal endothelium-independent relax-
ation to SNP was not affected (data not shown), this suggests an
impairment at the level of the endothelium rather than a vascular
smooth muscle cell defect. In the presence of indomethacin, a
COX-inhibitor, the EDR response to ACh markedly improved in
ZDF rats, indicating that contractile prostaglandins (PGs) opposed
normal relaxation (Figure 5B).
Effects of VIL and NWT-03 supplementation in ZDF rats
(Table 2)
GLP-1 levels trended higher (,1.4-fold) after NWT-03 treat-
ment (although this difference did not reach statistical signifi-
cance), and were profoundly increased (,5-fold, p,0.001) by
VIL. Despite these effects, neither agent improved any of the
metabolic parameters studied. Although the diabetic state was not
prevented, urinary MDA, an index of lipid peroxidation, was
slightly lower after supplementation, particularly with NWT-03.
Both VIL- and NWT-03-treated rats also showed significant
improvement in certain parameters of renal inflammation and
structural damage. Specifically, renal expression of IL-1b and IL-
13 mRNA, representative indicators of inflammatory cytokine
production, was reduced after VIL and NWT-03 (Figure 2), as was
the severity of FGS (Figure 3). In conjuction herewith the
expression of a-SMA and KIM-1 as markers of pre-fibrosis and
tubular damage were also reduced, albeit of borderline signifi-
cance. Interestingly, renal mRNA expression of the pro-inflam-
matory marker TNFa was also reduced, but only after NWT-03
treatment (Figure 2). The NWT-03-treated group was additionally
distinguished by a reduction in renal P22phox and COX-1/2
protein expression, an action not produced by supplementation
with VIL (Figure 4). Similarly, only NWT-03 reversed the
decrease in renal TXA2R protein.
Aortic EDR responses to ACh after VIL were comparable to
those in untreated ZDF rats, and were similarly sensitive to COX-
inhibition with indomethacin. In contrast, EDR responses were
improved after NWT-03 and were significantly less influenced by
the presence of indomethacin (Figure 5).
Discussion
In the present study, daily oral intake of NWT-03 for 15 weeks
decreased renal damage in diabetic ZDF rats, reducing FGS and
albuminuria by about 50%. In addition, impaired EDR responses
to ACh, an indicator of endothelial dysfunction, was improved in
ZDF rats after NWT-03. These findings demonstrate the
beneficial effects of long-term NWT-03 supplementation in
mitigating the development of renovascular damage in this
preclinical model of DM2.
Development of renovascular damage in the ZDF rat
model of DM2
The present findings with ZDF rats are consistent with those
reported previously. Already at a young age, obese ZDF rats
showed profound hyperinsulinemia and the first signs of hyper-
glycemia, hyperglycation, and dyslipidemia. At the end of the
study period, when rats were 25 weeks of age, serum insulin had
declined to lean levels and blood glucose had dramatically
increased. A similar relationship between insulinopenia due to
exhaustion of pancreatic beta cell function and progressive, severe
hyperglycemia has been observed previously, both in ZDF rats
[17] and patients with DM2 [18]. Because of this physiological and
metabolic profile, the ZDF rat is regarded a relevant model for
humans with DM2 [19].
In addition to a metabolic DM2 profile, ZDF rats develop
progressive nephropathy and renal failure [17,20–22]. Albumin-
uria, the earliest detectable clinical abnormality in diabetic
glomerulopathy, increased over time and was accompanied by a
,5-fold increase in FGS at the end of the study period. At that
time, urinary MDA was also increased in ZDF rats, as was renal
abundance of the P22phox subunit of NAD(P)H oxidase. This is in
line with previous reports depicting the ZDF rat as a model of
increased oxidative stress [22,23]. Enhanced production of
reactive oxygen species (ROS) and advanced glycation end
products induced by high glucose are believed to elicit inflamma-
tion and alter gene expression of growth factors and cytokines
implicated in diabetic nephropathy. Consistent with this, renal
mRNA analyses suggested an increase in the expression of
VCAM-1 with concomitant infiltration of white blood cells
(CD68) and production of inflammatory cytokines (TNFa, Il-1b,
Il-13) in ZDF rats, resulting in injury to renal cells and a
phenotypic change in matrix-forming myofibroblasts (staining for
KIM-1 and aSMA).
COX-derived PGs play important roles in maintaining renal
function, but may also be involved in the pathogenesis of diabetic
Figure 3. Renal morphology and FGS. (A) Shown are representative
sections for lean control rats (top left) and untreated ZDF rats (top
right), and ZDF rats supplemented with NWT-03 (bottom left) or treated
with VIL (bottom right). (B) FGS (see Methods); data are means 6 SEMs
(***p,0.001 vs. lean; #p,0.05 vs. ZDF).
doi:10.1371/journal.pone.0046781.g003
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nephropathy [24–26]. Komers et al. [27] reported an increase in
kidney abundance of COX-2 protein in 4- and 12-week-old ZDF
rats that was associated with enhanced urinary excretion of PGs
and parallel metabolic abnormalities. In the present study, the
renal abundance of both COX-1 and -2 protein were increased in
25-week-old ZDF rats, whereas TXA2R protein expression was
decreased. This latter effect (PG receptor down-regulation) may
reflect a response to increased production of PGs following up-
regulation of COX protein. Notably, the impaired EDR response
to ACh in the present study was fully restored in ZDF aortic rings
pre-incubated with indomethacin, a non-selective inhibitor of
COX. Recently, Retailleau et al. [28] reported elevated plasma
TXB2 (a TXA2 metabolite) in association with increased vascular
superoxide production and COX-2 expression in mesenteric
arteries of ZDF rats, and reduced AT2 receptor-mediated
vasorelaxation. Dilation in that study returned to the control level
after acute superoxide reduction, COX-2 inhibition, or TXA2
synthesis inhibition. Although we did not analyze aortic protein
abundance, the similar directionalities of renal COX protein
expression and functional effects of vascular COX-inhibition in
the present study appear to mutually reinforce the role of COX-
Figure 4. Renal expression of (A) COX-1, (B) COX-2, (C) TXA2R, and (D) P22
phox protein. Shown are results for lean control and untreated
ZDF rats, and ZDF rats supplemented with NWT-03 or treated with VIL. Data are expressed relative to GAPDH and are presented as means 6 SEMs
(*p,0.05, **p,0.01, and ***p,0.001 vs. lean; #p,0.05 vs. ZDF).
doi:10.1371/journal.pone.0046781.g004
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derived PGs in the development of renovascular damage in this
model.
Long-term effects of VIL and NWT-03
The starting point for this study was the previous demonstration
that NWT-03 exhibited mild in vitro and in vivo DPP4- and ACE-
inhibitory activities, both of which could, in theory, help to
improve glycemic control and/or limit renovascular end-organ
damage in DM2. The effects of ACE-inhibitor therapy in ZDF
rats have been studied to a certain extent, but relatively few studies
have addressed the effects of chronic DPP4-inhibitor treatment on
renovascular damage in this model. Therefore, as a frame of
reference for the effects of supplementation with NWT-03 on the
development renovascular damage in the present study, a parallel
group of ZDF was treated with the DPP4-inhibitor VIL.
DPP4-inhibitors—the latest addition to the list of available
antidiabetes agents—increase the activity of GLP-1 and glucose-
dependent insulinotropic peptide and have been found effective in
lowering glycated hemoglobin, and fasting and postprandial
glucose levels [29,30]. In insulin-resistant, non-diabetic Zucker
fatty rats, VIL, delivered as a single oral dose, was shown to induce
a dose-dependent inhibition of DPP4, enhance glucose-induced
increases in intact GLP-1, decrease postload glucose excursions,
and increase the insulinogenic index; the maximally effective dose
was reported to be 3 mg/kg, and nearly identical effects were
obtained with chronic treatment [8]. In the present study with
diabetic ZDF rats, chronic administration of VIL at the same dose
profoundly increased basal GLP-1 levels. But notwithstanding this
action, fasting blood glucose and HbA1c were not significantly
changed. In a previous study in ZDF rats, chronic treatment with a
different DPP4-inhibitor (FE 999011; 10 mg/kg per os, twice a
day) delayed, but did not prevent, the onset of hyperglycemia [31].
Our results may also be in line with a recent study by Thomas et
al. [32] in which chronic treatment with VIL (3 mg/kg/day for 5
weeks) reduced postload glucose excursion in ZDF rats, but not the
24-hour glucose profile in the fed state or HbA1c levels. In that
study, only chronic treatment with the long-acting DPP4 inhibitor
BI 1356 resulted in an overall glucose-lowering effect, whereas the
short-acting VIL did not.
Interestingly, FGS and renal tissue Il-1b and Il-13 mRNA
expression were reduced after VIL in the present study. This
suggests an action of VIL independent of its modulation of
metabolic parameters. DPP4 is abundantly expressed in the
proximal tubules in the kidney; and in human glomerular
endothelial cells, high glucose may increase the expression and
activity of DPP4 [33]. Furthermore, the CD26/DPP4 system is
known act through its DPP4 enzymatic activity to play a key role
in immune function as a T-cell activating molecule and regulator
of the functional effects of selected biological factors [34]. To our
knowledge, this is the first study reporting attenuated FGS
together with reduced renal Il-1b and Il-13 mRNA expression
after chronic treatment with the DPP4 inhibitor VIL in ZDF rats.
Of note, NWT-03 exerted the same effects, yet without
significantly altering circulating GLP-1 levels. Taken together,
these findings suggest that VIL and NWT-03 may share a similar
mode of action on the kidney that is independent of systemic
DPP4 inhibition and/or metabolic improvement. One plausible
explanation is that these agents acted locally in renal tissue, a
possibility that may be the subject of future studies. Such studies
may additionally include comparisons to incretin mimetics such as
exenetide to further mechanistically detail the effects of DPP4-
inhibition versus per se GLP-1 receptor agonism in diabetic
kidney.
Unlike VIL, NWT-03 also normalized renal TNFa mRNA and
P22phox protein expression, and significantly reduced urinary
MDA. Furthermore, increased renal COX-1/2 protein abun-
dance was normalized, and urinary albumin excretion was
reduced after NWT-03, but not VIL. Hence, it seems unlikely
that these latter effects of NWT-03 resulted from (local) DPP4
inhibition. Instead, it is more likely that they are related to the
Figure 5. EDR response to ACh in isolated aortic rings. (A) ACh-
induced relaxation in untreated ZDF rats was significantly reduced
compared to that in lean controls. Relaxations were significantly
increased in ZDF rats supplemented with NWT-03, but not in those
treated with VIL. Pre-incubation with the COX-inhibitor indomethacin
(INDO) profoundly improved relaxation to ACh in untreated ZDF rats
(not shown in panel A; see lean vs. ZDF in panel B). The area under the
curve (AUC) for ACh-induced relaxation in the absence and presence of
INDO was determined for each group and used to calculate the
percentage improvement. Data are means 6 SEMs; significant
differences are as indicated (repeated measures ANOVA). (B) Acute
COX inhibition improved ACh-induced relaxation to a significantly
smaller extent in ZDF rats supplemented with NWT-03, indicating a
diminished suppression of relaxation by contractile PGs in the latter
rats. Data are means 6 SEMs (***p,0.001 vs. lean; #p,0.05 vs. ZDF).
doi:10.1371/journal.pone.0046781.g005
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ACE-inhibitory activity of NWT-03 we observed in preliminary
studies. Angiotensin II—acting via increased production of
autocrine factors, such as TNFa, and up-regulation of NAD(P)H
oxidase subunits and production of ROS—has a key role in renal
injury and in the progression of chronic renal diseases of diverse
etiologies [35]. Angiotensin II-mediated inflammation and oxida-
tive stress may contribute to up-regulation of COX-2, whose
expression is induced by ROS [36,37]. Conversely, blocking the
AT1 receptor blocker has been shown to reverse up-regulation of
renal COX-2 and other pro-oxidant/inflammatory systems in
obese Zucker rats, and prevent the associated glomerulopathy and
proteinuria [38].
The enhancing effect of NWT-03 on endothelial function
observed here is also more likely attributable to the ACE-
inhibitory properties of NWT-03 than inhibition of DPP4, given
the lack of an effect of VIL on EDR. ACE inhibitors and AT1
receptor blockers prevent hyperglycemia-induced oxidative stress
by modulating angiotensin action and production; this is of
particular interest because hyperglycemia is able to directly
modulate cellular angiotensin generation [39]. In a study by
Oltman et al. [40] in ZDF rats, treatment with the ACE inhibitor
enalapril reduced vascular oxidative stress and improved mesen-
teric and coronary endothelial dysfunction independent of changes
in metabolic parameters (blood glucose, cholesterol, triglycerides,
and FFAs), which were not significantly reduced by ACE
inhibition. Notably, not only was the EDR response to ACh
significantly enhanced after NWT-03 in the current study, its
acute modulation by indomethacin was markedly smaller,
suggesting that functional down-regulation of COX-derived
contractile PGs by NWT-03 contributed to improved vascular
endothelial function. This effect of NWT-03 occurred in parallel
with reduced renal COX protein expression, and both actions
might be accounted for by inhibition of ACE (as suggested above).
Whether NWT-03 also exerts direct COX-inhibitory effects and/
or whether other additional mechanisms may contribute to its
long-term effects should be addressed in future studies.
In summary, dyslipidemia and prolonged hyperglycemia
promote an increase in oxidative stress, inflammation and vascular
damage, which together underlie diabetic nephropathy and
promote endothelial dysfunction and the associated micro- and
macrovascular complications. Employing the ZDF rat as a
preclinical model of DM2, we found that (1) long-term supple-
mentation with NWT-03 exerted a beneficial effect by attenuating
renal damage development and preventing aortic endothelial
dysfunction, likely through a mechanism involving decreased
oxidative stress and down-regulation of COX expression, and (2)
VIL produced a favorable effect—albeit it more limited—on renal
pro-inflammatory cytokines and glomerulosclerosis independent of
systemic improvement of metabolic parameters. Based on a
comparison to the DPP4-inhibitor VIL, the results suggest that the
effects of NWT-03 in the present study were related to its ACE-
inhibitory activity in addition to its DPP4-inhibitory properties. As
advanced by the American Diabetes Society [41], medical
nutrition therapy is important in preventing diabetes, managing
existing diabetes, and preventing, or at least slowing, the rate of
development of diabetes complications. This therapeutic strategy
includes secondary and tertiary interventions through healthy
nutrition and functional foods for individuals with diabetes and
seeks to prevent (secondary) or control (tertiary) complications of
diabetes. By analogy with current trends in the field of drug
research [9], the development and analysis of protein hydrolysates
that follow a multiple-targeting strategy may prove to be of benefit
in functional food formulations.
Table 2. Characteristics of 25-week-old ZDF rats after 15 weeks of treatment.
ZDF (n=7) ZDF+NWT-03 (n=9) ZDF+VIL (n=7) One-way p-value
Body weight (g) 427620 435615 42667 0.894
Left kidney weight (mg) 2154647 2285682 2274656 0.387
Right kidney weight (mg) 2199674 2369668 2258674 0.243
Hemodynamic parameters
Aorta HR (bpm) 226614 229610 240611 0.693
Aorta SBP (mmHg) 12464 11666 11667 0.544
Metabolic parameters
Glucose (mmol/L) 23.961.72 23.260.95 21.562.38 0.594
Hb1Ac (%) 9.5460.16 9.3360.20 9.0060.20 0.189
Insulin (ng/mL) 28.564.6 38.465.2 33.664.4 0.374
Cholesterol (mmol/L) 7.3360.19 7.0560.31 6.5260.49 0.312
FFAs (mmol/L) 0.6660.14 0.8960.26 0.3060.12 0.231
GLP-1 (pmol/L) 6.2260.38 8.6661.49 32.066.0*** ,0.001
Urinary parameters
Albumin (mg/24 h) 77.4615.7 43.964.5* 125.3616.3* ,0.001
Glucose (category) .7.0 .7.0 .7.0 n.d.
MDA:Creatinine 4.4461.03 2.2460.15* 3.5260.44 0.035
24-h Urine volume (mL) 7568 5466 122614** 0.001
Abbreviations: HR, heart rate; bpm, beats per minute; SBP, systolic blood pressure; FFAs, free fatty acids; GLP-1, glucagon-like peptide 1; MDA, malondialdehyde; n.d. not
determined.
Data are means 6 SEMs (*p,0.05, **p,0.01 and ***p,0.001 vs. untreated). P-values for one-way ANOVAs are indicated in the last column.
doi:10.1371/journal.pone.0046781.t002
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Supporting Information
Figure S1 Acute effects of oral NWT-03 and VIL on
plasma DPP4 activity and blood pressure in ZDF rats.
DPP4 activity and blood pressure were determined 1.5 hours after
administering NWT-03 (1 g/kg) or VIL (3 mg/kg) in 1 mL water
to anesthetized ZDF rats via a gastric tube. (A) Plasma DPP4-
activity was mildly inhibited in ZDF rats receiving NWT-03
(,25% decrease from baseline) and was profoundly inhibited in
those receiving VIL (,65% decrease from baseline), but was
unaffected in those receiving water only. (B) Systolic blood
pressure was unaffected by administration of NWT-03 or VIL.
Data are means 6 SEMs (*p,0.05 for ZDF vs. ZDF+NWT-03;
***p,0.001 for ZDF vs. ZDF+VIL; n = 6–9 per group).
(TIF)
Figure S2 Acute effect of oral NWT-03 on plasma ACE
activity and blood pressure in SHRs. ACE activity and
blood pressure were determined 1.5 hours after administering
NWT-03 (1 g/kg) in 1 mL water to anesthetized SHRs via a
gastric tube. (A) Plasma ACE activity was mildly inhibited (,25%
decrease from baseline) and (B) systolic blood pressure was
reduced (,30% decrease from baseline) in animals receiving
NWT-03, but not in those receiving water only. Data are means6
SEMs (*p,0.05 for SHR vs. SHR+NWT-03; n= 5 per group).
(TIF)
Table S1 Primers used for real-time PCR.
(DOC)
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